Department of Dermatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.
Br J Dermatol. 2010 Jul;163(1):128-37. doi: 10.1111/j.1365-2133.2010.09694.x. Epub 2010 Feb 15.
Keratinocytes can obtain cholesterol either by de novo synthesis or by extraction, primarily from low-density lipoprotein (LDL). LDL is internalized following binding to the LDL receptor (LDLR). Because LDLR is expressed at a higher level in the cells of the basal layer of the epidermis, it might be assumed that LDLR upregulation is associated with keratinocyte proliferation. However, the effect of LDLR stimulation on keratinocyte function remains unclear.
To investigate the effects and mechanism of action of pitavastatin and effects of LDL on proliferation and migration of keratinocytes.
Pitavastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, was used to induce upregulation of LDLR. LDLR expression was evaluated by immunofluorescence staining, fluorescence-activated cell sorting, immunohistochemical staining and real-time polymerase chain reaction (PCR). HaCaT cells and normal human keratinocytes (NHKs) were used for evaluation of migration. 5-Bromo-2'-deoxyuridine incorporation was used to evaluate keratinocyte proliferation and differentiation. C57BL6 mice were used for in vivo evaluation of the effect of topical pitavastatin or lovastatin.
Pitavastatin was most effective in LDLR induction at a concentration of 1 micromol L(-1) in NHKs. Real-time PCR showed that pitavastatin significantly increased LDLR and liver X receptor (LXR) beta mRNA expression in these cells. Similar results were obtained in vivo. However, pitavastatin had no effect on the migration of NHKs. After the addition of LDL and/or mevalonate concomitantly with pitavastatin to NHK cultures, or topical application of pitavastatin on mouse skin, keratinocyte proliferation was significantly increased.
Pitavastatin significantly upregulates LDLR in both NHKs and C57BL6 mouse skin, resulting in increased keratinocyte proliferation. LXRbeta may be involved in the pitavastatin-induced keratinocyte proliferation.
角朊细胞可以通过从头合成或提取(主要从低密度脂蛋白[LDL]中)获得胆固醇。LDL 与 LDL 受体(LDLR)结合后被内吞。由于 LDLR 在表皮基底层细胞中的表达水平较高,因此可以假设 LDLR 的上调与角朊细胞增殖有关。然而,LDLR 刺激对角朊细胞功能的影响尚不清楚。
研究匹伐他汀的作用及其作用机制,以及 LDL 对角朊细胞增殖和迁移的影响。
使用 3-羟基-3-甲基戊二酰基辅酶 A 还原酶抑制剂匹伐他汀诱导 LDLR 上调。通过免疫荧光染色、荧光激活细胞分选、免疫组织化学染色和实时聚合酶链反应(PCR)评估 LDLR 表达。使用 HaCaT 细胞和正常人角质形成细胞(NHK)评估迁移。5-溴-2'-脱氧尿苷掺入用于评估角朊细胞增殖和分化。使用 C57BL6 小鼠进行匹伐他汀或洛伐他汀局部应用的体内评价。
匹伐他汀在 NHK 中最有效地在 1 微摩尔/升浓度下诱导 LDLR。实时 PCR 显示,匹伐他汀显著增加了这些细胞中的 LDLR 和肝 X 受体(LXR)β mRNA 表达。在体内也得到了类似的结果。然而,匹伐他汀对角朊细胞的迁移没有影响。在向 NHK 培养物中添加 LDL 和/或甲羟戊酸以及匹伐他汀,或在小鼠皮肤表面局部应用匹伐他汀后,角朊细胞增殖显著增加。
匹伐他汀在 NHK 和 C57BL6 小鼠皮肤中均显著上调 LDLR,导致角朊细胞增殖增加。LXRβ 可能参与了匹伐他汀诱导的角朊细胞增殖。